In the current study we sought to address if EP3 blockade or EP4 activation could improve cardiomyocyte function under hyperglycemic conditions, and if treatment with an EP3 antagonist in vivo could improve cardiac function in the db/db mouse model of T2D. This evidence concerns the gene PTGER4 and type 2 diabetes mellitus.